Kornimate/medical-research-clean huggingface dataset:
effects of intermittent hypoxia (ih) on metabolism and dysglycemia, in overweight/obese persons sci

Conditions: Spinal Cord Injuries; Obesity; Insulin Resistance

Summary: the purpose of this research is to examine changes in blood glucose control and metabolism in individuals with sci and non injured controls at rest and during exercise after five days of exposure to ih. this response will be compared with breathing normal room air (a sham control).


Eligibility criteria:
inclusion criteria: sci only: 1. lower extremity weakness or paralysis at c5 or below resulting from spinal cord injury for at least one year. 2. asia classification a-d overweight or obese as classified by a body mass index (bmi) (kg/m2) of ≥ 25.0 (con) and ≥ 22.0 (sci). sci and non injured control: resting sao2 ≥ 95% exclusion criteria (sci and non injured control): 1. currently hospitalized 2. resting heart rate ≥120 bpm 3. resting systolic blood pressure \>180 mm hg 4. resting diastolic blood pressure \>100 mmhg 5. self-reported history of unstable angina or myocardial infarction within the previous month 6. previous cardiac surgery or condition that evidences ischemic heart disease 7. cardiopulmonary complication such as copd 8. pregnancy determined by urine testing in sexually active females.

Keywords: spinal cord injuries obesity insulin resistance intermittent hypoxia
how total knee prosthesis dessigns influence in quality of live

Conditions: Osteoarthritis Knee; Total Knee Replacement

Summary: the purpose of this study is to determine whether different kind of prostesis designs influences in the quality of life of patients

objectiu criteris d'inclusió mesura dels resultats

Eligibility criteria:
inclusion criteria: * aged 65-80 years. * primary ostheortritis * mechanical axis 0+/- 7 degrees exclusion criteria: * patients with any new important disease after the surgical procedure. * important complications related with the surgical procedure, as fractures, infections and vascular lesions. * patients not following a rehabilitation program

Keywords: osteoarthritis knee total knee arthroplasty quality of life
the association of serpina1 gene disturbance in patients with lung and gum disorders

Conditions: Pulmonary Disease, Chronic Obstructive; Generalized Chronic Periodontitis

Summary: chronic obstructive pulmonary disease and periodontitis are chronic inflammatory diseases. the study aims to determine if the genetic polymorphism of serpina1 gene in patients with copd serve as a risk factor for developing periodontitis.

periodontitis is a polymicrobial inflammatory disease caused by various modifiable and non-modifiable risk factors. the non-modifiable risk factors include genetic polymorphisms like the gene coding for alpha-1-antitrypsinase copd is a chronic inflammatory disease characterized by deterioration of lung function due to loss of elasticity of the lungs. serpina1 gene product has a protective role on the connective tissue components of both lungs and gums. hence, this study tries to determine if the gene polymorphism in copd serves as a risk factor for developing periodontitis.

Eligibility criteria:
inclusion criteria: * male and female patients aged between 30-70yrs diagnosed with copd and chronic periodontitis who are willing to participate in the study. exclusion criteria: * pateints with other systemic disorders * patients not willing to participate in the study

Keywords: pulmonary disease,chronic obstructive, generalized chronic periodontitis serpina1 gene polymorphism
efficacy of beta-hydroxy-beta-methylbutyrate (hmb) supplementation in hemodialysis patients

Conditions: Complication of Dialysis; Chronic Kidney Disease; Muscle Loss; End Stage Renal Disease

Summary: the purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (hmb) supplementation on the physical function and the health of bones, arteries and heart in hemodialysis patients.

patients with renal failure receiving hemodialysis experience an increased rate of skeletal muscle protein catabolism which is associated with a number of co-morbid conditions including declines in muscle mass and strength, significantly increased fall risk, and reduced quality of life (qol. therefore, interventions to prevent muscle loss in hemodialysis are needed. pharmacological agents have been investigated to treat muscle loss in dialysis patients; however, many of these treatments are expensive and have undesirable side effects. as a result, low-cost interventions designed to attenuate losses in muscle mass and strength in hemodialysis patients are needed. beta-hydroxy beta-methylbutyrate (hmb) represents a potential low-cost nutritional intervention to attenuate muscle loss in hemodialysis patients. hmb is a metabolite of the amino acid leucine that has been shown to safely increase muscle mass in other clinical populations with prevalent muscle loss, such as the elderly, cancer, and aids patients primarily through reductions in skeletal muscle protein catabolism. the primary purpose of the trial is to determine if oral supplementation with hmb attenuates muscle loss, improves muscle strength, physical function, fall risk and qol in hemodialysis patients. alterations in protein and gene expression associated with skeletal muscle protein turnover will be measured to investigate the mechanism for changes in our primary outcomes. we hypothesize that hmb supplementation will attenuate declines in muscle size and strength in hemodialysis patients.

Eligibility criteria:
inclusion criteria: * must be receiving hemodialysis treatment. * must be willing to be randomized to hmb or placebo for 6 months * must receive physician clearance to participate exclusion criteria: * bodyweight \> 350 lbs * currently taking an hmb supplement or hmb containing products (eg. ensure)

Keywords: hemodialysis physical function
effects on pes planus exercise training mixed with play on pre-school children

Conditions: Pes Planus; Flat Foot; Femoral Anteversion

Summary: the study was planned to assess effects on pes planus and femoral anteversion angle of exercise training mixed with play on pre-school children.

pes planus ( pes planovalgus) is similar with flatfoot occurs collapse of medial longitudinal arch which is lower than normal range or occurs extra pressure on arch. it is separated two group such congenital (flexible and rigid) and acquired. the etiology of pes planus is that hallux rigidus, plantar calcaneonavicular ligament rupture, collapse of medial longitudinal arch, pathology of ligament and tendon, shortness achilles tendon and juvenile hallux valgus. the most common causes of pes planus are outgroup of leg muscles (peroneal) spasticity, plantar fasciitis and tibial tendon insufficiency. symptoms of pes planus are indicated heel pain, gait abnormalities, decreased dorsiflexion range of ankle, plantar ulceration, limited mobility of 1.metatarsophalangeal joint and spasm of peroneal muscle. there is a high prevalence rates among males and occur positive correlation between with pes planus and bmi. evaluation methods of pes planus are x-ray, heel height, gait analysis and achilles strain. the most commonly used method are line that medial malleolus, 1st metatarsal head and the navicula is on the same line, and the footprint technique from ink rubber plates. treatment of pes planus is maintained medial displacement calcaneal osteotomy operation with the transfer of the flexor digitorum longus. non- invasive treatment methods are given such as peroneal muscles and achilles stretching exercises. 25 degree angle inverted foot orthoses are commonly used because of increasing stance phasic in treatment. peroneal neural mobilization, play training and stretching exercises are often used treatment method of pes planus. main purpose of this study is that assess effects of mixed training program with playing on pes planus and increased femoral anteversion angle in pre-school students.

Eligibility criteria:
inclusion criteria: * children in an age range of 4-7 years, * having bilateral or unilateral deformity with pes planus * csi range \> % 62.7 measured by the referring physical therapist. * having no any foot surgeon, * without any neurological diseases, * who want to be involved voluntary work, * pre-school students who have been informed by their families(their families approved illuminated affirmation ). exclusion criteria: * pre-school students who can not adapt to training, * students who do not want to be involved in voluntary work.

Keywords: pedography exercise play training pes planus femoral anteversion
efficacy of stellate ganglion block in traumatic brain injury patients

Conditions: Traumatic Brain Injury

Summary: the goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in traumatic brain injury patients. the main question it aims to answer are: can stellate ganglion block improve the dysphagia and activities of daily living in traumatic brain injury patients. traumatic brain injury patients will be divided into the the control group and observation group evenly. all the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. the swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

dysphagia, or swallowing difficulty, is a common symptom in traumatic brain injury patients. the goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in traumatic brain injury patients. the main question it aims to answer are can stellate ganglion block improve the dysphagia and activities of daily living in traumatic brain injury patients. traumatic brain injury patients will be divided into the the control group and observation group evenly. all the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. the swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, meeting the diagnosis of traumatic brain injury; * presence of no contraindication for stellate ganglion block; * with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications; * informed consent form was obtained from the patient. exclusion criteria: * unable to cooperate in completing treatment and assessment due to personal reasons or other disorders; * complicated with other intracranial lesions, such as stroke; * with severe consciousness disorders caused by other diseases.
absolute quantification in bone scintigraphy

Conditions: Scintigraphy Quantification

Summary: while absolute quantification in 18f-fdg pet (positon emission tomography) is widely used in clinical routine, absolute quantification in spect (single photon emission computed tomography) is under development and its clinical interest remains to be demonstrated. recent studies carried out on bone scan recordings show the potential interest of quantification indexes such as suv (standard uptake value).

in oncology, bone scan studies have reported significantly higher suv values for secondary bone lesions compared with benign osteoarticular lesions , and some have even defined an suvmax threshold value that points to prostatic bone metastases.

Eligibility criteria:
inclusion criteria: * patients with recent vertebral fractures: 1. who have had at least two spect/ct scan scans of the spine as part of a pre-vertebroplasty check-up, 2. for which fracture dates were known. exclusion criteria: 1. minor person 2. person opposing the use of their data (posters in waiting rooms explaining that the patient must object if they do not wish their data to be used)

Keywords: bone scintigraphy absolute quantification standard uptake value
a pilot study to promote maternal and infant oral health

Conditions: Dental Caries

Summary: the long term goals of this project are to develop and implement a combined prenatal and postnatal intervention to decrease early childhood caries. the program is based on risk assessment, diet intervention and counseling. to accomplish these goals a pilot study is needed to determine: 1) the ability to recruit and retain pregnant mothers in an intervention program; 2) the levels of s. mutans in pregnant mothers; 3) the ability of a diet intervention to decrease s. mutans in pregnant mothers.


Eligibility criteria:
inclusion criteria: * age 18 or over; * pregnant * high s. mutans levels exclusion criteria: * younger than 18; * other health conditions
assess the safety and efficacy of nephoxil® in subjects with end stage renal disease (esrd) on dialysis

Conditions: Kidney Failure, Chronic; End-stage Renal Disease; Phosphorus Metabolism Disorders; Hyperphosphatemia

Summary: to assess the long-term safety and effectiveness of nephoxil® for the treatment of hyperphosphatemia in patients with esrd undergoing dialysis.

this study is an open-label, prospective, long term, phase iv study to assess the safety and efficacy of nephoxil® in subjects with esrd on dialysis.

Eligibility criteria:
inclusion criteria: 1. is ≧ 18 years of age on the day of signing informed consent or other age required by local regulation 2. willing and able to provide written informed consent 3. esrd patients who is undergoing hemodialysis 3 times per week and is considered necessary to receive medication for hyperphosphatemia by his/her treating physician 4. serum ferritin \<1000 ng/ml and transferrin saturation (tsat) \< 50% at the enrollment visit 5. women of child-bearing potential (wocbp \[defined as women ≤ 50 years of age with a history of amenorrhea for \< 12 months prior to study entry\]) who is willing to use an effective form of contraception during study participation exclusion criteria: 1. has any known contraindication to ferric citrate according to locally approved prescribing information, include but not limited to the following criteria: i. is allergic to ferric citrate ii. has hypophosphatemia iii. has hemochromatosis or iron overload syndromes iv. has active severe gi disorders 2. has parathyroidectomy (ptx) or percutaneous ethanol injection therapy (peit) within 3 months prior to enrollment visit or serum calcium \< 7 mg/dl at the enrollment visit 3. has participated in another interventional study for any investigational agent or device within 30 days prior to enrollment 4. is currently pregnant or breastfeeding 5. other unstable medical condition or psychiatric conditions that is considered unsuitable for this study per investigator's clinical judgment

Keywords: citric acid ferric compounds renal insufficiency anticoagulants calcium chelating agents chelating agents sequestering agents hemodialysis dialysis renal failure kidney failure urologic diseases metabolic disease kidney diseases renal insufficiency, chronic
study of aro-inhbe in adults with obesity with and without diabetes mellitus

Conditions: Obesity

Summary: this is a phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (pk) and pharmacodynamics (pd) of single and multiple doses of aro-inhbe in adult participants with obesity (part 1), and the safety, tolerability and pd of multiple doses of aro-inhbe in adult participants with obesity with and without type 2 diabetes mellitus receiving tirzepatide (part 2).


Eligibility criteria:
inclusion criteria: * obesity, defined as body mass index (bmi) between 30 to 50 kg/m2 at screening * at least one self-reported, unsuccessful attempt at weight loss with lifestyle modification * willing, able and motivated to comply with all study assessments and adhere to the protocol schedule, including adherence to a stable diet and exercise routine for the duration of the study * no abnormal finding of clinical relevance at screening that, in the opinion of investigator, could adversely impact subject safety or adversely impact study results * participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the endo of the study or last dose of study medication, whichever is later. participants must not donate sperm or eggs during the study and for at least 90 days following the end of the study or last dose of study medication, whichever is later. exclusion criteria: * self-reported (or documented) weight gain or loss \>5% within 3 months prior to screening * use of glp1r agonists (liraglutide, semaglutide, etc.) for any indication within 6 months prior to screening * use of non-glp1r medications for weight loss within 3 months prior to screening, including but not limited to naltrexone/bupropion, orlistat, phentermine/topiramate, and other prescription or over-the-counter medication or supplements taken for weight loss * obesity attributable, in the investigator's opinion, to medication use, endocrinologic or monogenic disorders * history or prior surgical or device-based therapy for obesity * use of medications strongly associated with weight gain within 3 months prior to screening * type 1 diabetes mellitus * history of hyperthyroidism or thyroid-stimulating hormone (tsh) levels \ 6.0 miu/l at screening * evidence of clinically significant end-organ disease note: other inclusion/exclusion criteria may apply per protocol
outcome after multidisciplinary co2 laser laparoscopic excision of deep infiltrating colorectal endometriosis

Conditions: Endometriosis

Summary: improved pain, sexuality and quality of life, high fertility and low complication and recurrence rates after multidisciplinary co2 laser laparoscopic excision of deep infiltrating colorectal endometriosis.

all women (n=56) who had undergone co2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist were selected retrospectively from the list of all patients (n=more than 2000) operated at the leuven university fertility centre (lufc) between september 1996 and july 2004. all 56 multidisciplinary operated patients were asked to complete the oxford endometriosis quality of life questionnaire, a sexual activity questionnaire and visual analogue scales (vas) for dysmenorroe, chronic pelvic pain and deep dyspareunia, to compare their status before surgery and at the moment of the evaluation (january 2005).

Eligibility criteria:
inclusion criteria: * all women (n=56) who had undergone co2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist * operated at the leuven university fertility centre (lufc) between september 1996 and july 2004 exclusion criteria: * women who had undergone co2 laser laparoscopic excision of deep infiltrating endometriosis without active involvement of colorectal surgeon and/or urologist

Keywords: colorectal endometriosis deep infiltrating endometriosis dysmenorroe dyspareunia quality of life
assessment of the natural antibody response to pneumococcal surface proteins during acute otitis media in children

Conditions: Acute Otitis Media

Summary: this clinical study is designed to assess prospectively the sero-responses to various proteins in cases of pneumococcal acute otitis media.


Eligibility criteria:
inclusion criteria: * male and female jewish and bedouin children. * patients can be either ambulatory or hospitalized. * presenting with acute otitis media. * tympanocentesis was performed at least in one ear for a clinical indication. * culture of middle ear fluid was obtained. * parents agreeing to participate in the study and to submit their children for follow-up, blood test and nasopharyngeal/oropharyngeal (np/op) cultures. exclusion criteria: * having another infection that is likely to be caused by s. pneumoniae. * known immunodeficiency. * known previous recent pneumococcal infections (\<1 month prior to current visit).

Keywords: vaccine pneumococcal natural history acute otitis media
vigilant observation of gliadel wafer implant registry

Conditions: CNS Tumor

Summary: this is a prospective, observational registry in patients who have been prescribed gliadel wafer by the physician as part of usual care.

this is a prospective, observational registry in patients who have been prescribed gliadel wafer by the physician as part of usual care. data will be collected on the safety and effectiveness of treatment with gliadel wafer perioperatively and ongoing during regular office visits up to 3-years. patients enrolled in this registry will be asked to complete a questionnaire (functional assessment of cancer therapy-brain \[fact-br\]) about their well-being and clinicians will complete the karnofsky performance status (kps) during office visits.

Eligibility criteria:
inclusion criteria: 1. signed informed consent, by the patient or a legally acceptable representative, obtained before any registry-related activities are undertaken. the informed consent must be signed within 14 calendar days after surgery. 2. male and female patients, greater than or equal to 18 years of age or age of majority in state of residence. 3. patients planning to receive gliadel wafer, or having already received gliadel wafer and having signed consent to enroll in the registry within 14 calendar days after surgery for treatment of central nervous system (cns) tumor(s), or are currently enrolled in another study where they received gliadel wafer. 4. signed release form, by the patient or a legally acceptable representative, permitting abstraction of the patient's medical records at baseline and during participation in the registry. exclusion criteria: 1. the patient is enrolled in an interventional clinical trial, in which treatment for cns tumor(s) is managed through a protocol that excludes gliadel wafer treatment. 2. any abnormality or medical condition that, at the discretion of the investigator, may put the patient at increased risk by participating in this registry. 3. any other reason that, in the investigator's opinion, makes the patient unsuitable to participate in this registry.

Keywords: gliadel, carmustine wafer implant